An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Lutetium-177-DOTA-satoreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions
- Sponsors Ipsen
- 17 Feb 2017 Status changed from not yet recruiting to recruiting.
- 30 Jan 2017 Planned initiation date changed from 1 Dec 2016 to 1 Jan 2017.
- 28 Dec 2016 Planned End Date changed from 1 Dec 2019 to 1 May 2022.